Fennec Pharmaceuticals (FENC) Stock Forecast & Price Target

Fennec Pharmaceuticals is attractive because PEDMARK is gaining commercial traction, with adoption broadening across new and existing accounts, deeper utilization, and seven consecutive quarters of sales growth culminating in 2Q26 net product sales of $17.2M, up 78% year over year. The company is also improving its financial quality, posting total revenue of $17.9M, first positive non-GAAP adjusted EBITDA of $2.8M, and cash and equivalents of $41.2M, while management expects cash generation by year-end. Longer-term upside comes from a potentially much larger addressable market if NCCN evidence improves from category 2A to category 1, supported by ongoing clinical initiatives, and from extended market exclusivity to at least September 1, 2033.

Fennec Pharmaceuticals is viewed negatively because the investment case is overly concentrated in PEDMARK, with 100% of revenue tied to one product and no internal pipeline, leaving the business exposed to patent litigation, competitive threats, and any slowdown in commercial uptake. The company’s growth also depends on challenging reimbursement dynamics, including off-label adult use supported by NCCN Category 2A and pediatric DRG-bundled economics that favor compounded STS at 70-90% price discounts, while cash of $42M as of December 2025 may prove insufficient if the commercial buildout outpaces revenue. Even with 1Q26 revenue of $15.1M and net earnings of $0.01 per share, the modest miss versus forecast and the reduction in 2026 and 2027 revenue and earnings estimates reinforce the view that profitability remains fragile.